After Hours
$
140.00
Change
+0.02 +0.01%
Volume
Volume 61,864
Jan 30, 2023, 6:02 p.m.
Quotes are delayed by 20 min
Previous close
$ 140.67
$ 139.98
Change
-0.69 -0.49%
Day low
Day high
$138.09
$141.43

52 week low
52 week high
$105.43
$183.00

Market cap
$26.12B
Average volume
909,457
P/E ratio
N/A
Rev. per Employee
$696,865
EPS
-3.46
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on SGEN
-
Incyte Corp. stock underperforms Monday when compared to competitors
- MarketWatch Automation
-
Incyte Corp. stock underperforms Friday when compared to competitors
- MarketWatch Automation
-
Incyte Corp. stock rises Thursday, outperforms market
- MarketWatch Automation
-
Incyte Corp. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock rises Tuesday, outperforms market
- MarketWatch Automation
-
Incyte Corp. stock rises Monday, still underperforms market
- MarketWatch Automation
-
Incyte Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock rises Thursday, outperforms market
- MarketWatch Automation
-
Incyte Corp. stock rises Wednesday, still underperforms market
- MarketWatch Automation
-
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains
- MarketWatch Automation
-
Lucid, Tesla, Nvidia, and AMD Led a Tech-Stock Rally
- Barron's Online
-
Incyte Corp. stock falls Monday, underperforms market
- MarketWatch Automation
-
Incyte Corp. stock rises Friday, still underperforms market
- MarketWatch Automation
-
Incyte Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock underperforms Wednesday when compared to competitors
- MarketWatch Automation
-
Incyte Corp. stock underperforms Tuesday when compared to competitors
- MarketWatch Automation
-
Incyte Corp. stock rises Friday, outperforms market
- MarketWatch Automation
- Loading more headlines...
Analyst Ratings
-
Wall Street Is Bullish on Nektar Stock despite Stock Price Slump
- MarketRealist.com
-
Benzinga's Top Upgrades, Downgrades For October 20, 2017
- Benzinga.com
-
Shkreli: I'd Short Immunomedics On The Bounce
- Benzinga.com
Other News on SGEN
-
Healthcare Deal-Making Set to Surge in 2023
- The Wall Street Journal Interactive Edition
-
This Insider Just Sold Shares of Seagen Inc
- GuruFocus.com
-
The Biotech Takeout Menu Gets Pricier
- The Wall Street Journal Interactive Edition
-
Merck Strikes $1.35 Billion Deal for Bone-Marrow Disease Drug Developer
- The Wall Street Journal Interactive Edition
-
Did You Buy And Not Sell Friday? You're Doing It Wrong - Again
- Seeking Alpha
-
Biogen Names Viehbacher New CEO
- The Wall Street Journal Interactive Edition
-
Seagen appoints former Novartis cancer czar as CEO
- Seeking Alpha
-
Healthcare Stocks Offer Refuge in Bruised Market
- The Wall Street Journal Interactive Edition
-
Genmab: Great Company, But Stock Is Not That Great
- Seeking Alpha
-
Merck: Great Medicine For The Portfolio
- Seeking Alpha
-
Top 5 3rd Quarter Trades of Lattice Capital Management, LLC
- GuruFocus.com
-
Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript
- Seeking Alpha
-
Seagen Inc. 2022 Q3 - Results - Earnings Call Presentation
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
- Loading more headlines...
Press Releases on SGEN
-
- MarketNewsVideo.com
-
Seagen to Present at the J.P. Morgan Healthcare Conference
- BusinessWire - BZX
-
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
- Financial News Media
-
- MarketNewsVideo.com
-
Seagen Appoints Sandra M. Swain, M.D., to Board of Directors
- BusinessWire - BZX
-
Seagen Names David R. Epstein as Chief Executive Officer and Director
- BusinessWire - BZX
-
Seagen Reports Third Quarter 2022 Financial Results
- BusinessWire - BZX
-
- MarketNewsVideo.com
-
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
- Financial News Media
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com